cellestia biotech
Cellestia is a bio-pharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway.
Total raised
€17M
€17,200,000
Funding rounds
2
Investors
2
distinct backers
Active since
2019-09
latest 2021-08
Funding by year
EUR raised per yearSignals
Medium confidenceRaise-next likelihood11
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Exit likelihood13
base rate 12% (2+ rounds)
- ▲ 12y since founding
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-08-16 | Other | — | SNGLR Capital | View deal → |
| 2019-10-01 | Series B | €17M | FC Capital | View deal → |
Investors
2Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy